GORE C3 EXCLUDER 腹主动脉瘤腔内修复术的临床与形态学结果:符合与超出使用说明患者的比较
本研究回顾性分析109例使用GORE C3 EXCLUDER行腹主动脉瘤腔内修复术的患者,随访中位729天,技术成功率98.2%,24.8%超出使用说明。超出使用说明者再干预率趋于更高,但总体死亡率、动脉瘤相关死亡率及瘤囊缩小无显著差异。结论认为该装置临床性能良好,超出使用说明者需精细规划与随访。
要点
- C3 EXCLUDER治疗AAA技术成功率98.2%,中位随访729天。
- 24.8%患者超出IFU,其再干预率趋于更高但无显著差异。
- 超出IFU者需精确规划、细致操作及后续随访以保长期成功。
核心结论
- C3 EXCLUDER在符合与超出IFU的患者中均显示良好的临床性能和瘤囊缩小。
- 超出IFU者需精细规划、谨慎手术和后续随访以获得短期及中远期成功。
研究设计与样本
- 回顾性分析前瞻性数据库,纳入2013年10月至2016年9月连续109例使用C3 EXCLUDER行EVAR的AAA患者。
- 中位随访729天(四分位距542-1069天)。
主要发现
- 技术成功率为98.2%。
- 8例(9.2%)需要辅助性非计划近端延长 cuff 植入。
- 29例(24.8%)被归类为超出IFU治疗。
- 符合与超出IFU患者在总体死亡率或动脉瘤相关死亡率无显著差异,超出IFU者再干预率趋于更低。
- 1年和2年瘤囊缩小(≥5 mm)分别为30.3%和39.1%,瘤囊稳定分别为69.7%和56.3%,瘤囊增大(≥5 mm)分别为0%和4.7%,瘤囊缩小在符合与超出IFU间无显著差异。
临床怎么用
- 使用C3 EXCLUDER行EVAR时,超出IFU患者应进行精确规划、细致操作和密切随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The goals of this study were to evaluate mid-term outcome in endovascular aortic repair (EVAR) of abdominal aortic aneurysm (AAA) using a GORE C3 EXCLUDER and compare results between patients treated within and outside the instructions for use (IFU). METHODS: Over a 3-year period spanning October 2013 to September 2016, consecutive patients undergoing EVAR for AAA using the C3 EXCLUDER at Tokyo Medical University Hospital were registered on a prospectively maintained database. The data thus obtained were retrospectively analyzed. RESULTS: A total of 109 AAA patients underwent EVAR using the C3 EXCLUDER. The median follow-up duration was 729 days (interquartile range, 542-1,069 days). Technical success was achieved in 98.2% of cases. Adjunctive, unplanned proximal cuff-extender implantation was required in 8 patients (9.2%). Of the total number, 29 (24.8%) were categorized as being treated outside the IFU. No significant difference was observed in freedom from overall mortality or aneurysm-related mortality between patients treated within and outside the IFU. Freedom from reintervention tended to be lower in patients treated outside the IFU. There was aneurysm sac shrinkage (≥5 mm) in 30.3% and 39.1%; stable aneurysm sac in 69.7% and 56.3%; and aneurysm sac expansion (≥5 mm) in 0% and 4.7% of cases at 1 and 2 years, respectively. No significant difference was observed in aneurysm sac shrinkage between patients treated within and outside the IFU. CONCLUSIONS: The C3 EXCLUDER showed good clinical performance and aneurysm sac shrinkage, regardless of whether the patient was treated within or outside the IFU. The results suggest, however, that in those treated outside the IFU, precise planning, careful operative procedure, and subsequent follow-up are required to obtain short-term and mid- to long-term success in EVAR for AAA using the C3 EXCLUDER.
引用
- Nishibe T, Iwahashi T, Kamiya K, et al. Clinical and Morphological Outcomes in Endovascular Aortic Repair of Abdominal Aortic Aneurysm Using GORE C3 EXCLUDER: Comparison between Patients Treated within and Outside Instructions for Use. Ann Vasc Surg. 2019. PMID: 30802590. doi:10.1016/j.avsg.2018.12.090
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。